Enterome, a France-based developer of treatments for gut microbiome-associated conditions, secured €32m ($38.5m) in series D funding yesterday from investors including pharmaceutical firms Bristol Myers-Squibb and Lundbeck.
The round also featured food producer Nestlé’s Health Science unit, as well as Seventure, Health for Life Capital, Omnes Capital and Principia. Lundbeck invested through its corporate venturing division, Lundbeckfonden Ventures.
Founded in 2012, Enterome is creating therapies for gut microbiome-associated conditions such as inflammatory bowel diseases and immuno-oncology indications. The technology is…
